Plasmodium Falciparum Malaria Clinical Trial
Official title:
Time to Infection With Malaria Parasites in Adults
This study will attempt to find out what effect mosquito insecticides have on the transmission of malaria in The Gambia. Eight hundred healthy men and women, aged 18 to 40 years, living in selected villages east of Farafenni town in The Gambia, West Africa will be screened for parasites. About 552 of these people are expected to be free of malaria and will form the study group. These people will participate in the study for 7 months and will be checked for the malaria-causing parasite every two weeks by finger prick blood sample.
Malaria remains one of the world's greatest childhood killers and is a substantial obstacle to social and economic development in the tropics. The overwhelming bulk of the world's malaria burden rests upon the population of sub-Saharan Africa because of the unique coincidence of expanding human populations, weak health systems, the world's most effective vector mosquito species and environmental conditions ideal for transmission. At the start of the new millennium malaria is still deeply entrenched in Africa and effective malaria control is under threat from the inexorable spread of parasite strains resistant to antimalarial drugs and the emergence of mosquitoes resistant to the pyrethroid insecticides used to impregnate bednets. Larval control may offer a new alternative for effective control. Mosquito larval control strategies (environmental management and larviciding) have historically been shown to be successful in reducing the abundance of mosquitoes. This study plans to apply a larvicide in an effort to control malaria and reduce the burden of malaria. While it is abundantly clear that this product will kill mosquito larvae in the laboratory and in the field, it is not certain that doing so will reduce the burden of malaria for the human population. Briefly, the steps involved include survival and development of immature mosquito stages, emergence of adult mosquitoes, blood feeding by those mosquitoes, acquisition and development of malaria parasites by adult mosquitoes and transmission of parasites to susceptible humans. The objective of this pilot study is to evaluate the use of the time-to-infection end point as a measure of malaria transmission in The Gambia, while mosquito larvicides are used to control malaria vectors. The main outcomes of this study are (1) the proportion of adults with detectable parasitemia (Plasmodium falciparum) that is a binary variable and (2) time-to-infection with malaria parasites that will be treated as a continuous variable. This experimental design takes place over 7 months. The target sample size is 800 adults (aged 18-40 years, approximately half will be women and half men) living in 50 villages east of Farafenni town in The Gambia, West Africa. It is estimated that 552 of the adults will have no detectable parasites in their blood at the beginning of the transmission season (June). These parasite negative individuals will be followed either for the duration of the transmission season (June through November) or until they become positive for parasites. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04577066 -
Safety and Preliminary Protective Efficacy of Genetically Attenuated GA2 Parasites.
|
Phase 1/Phase 2 | |
Completed |
NCT01883609 -
A Safety and Efficacy Study of ChAd63/MVA METRAP + RTS,S
|
Phase 1/Phase 2 | |
Completed |
NCT00593398 -
Malarial Immunity in Pregnant Cameroonian Women
|
||
Completed |
NCT01659281 -
Efficacy of Artesunate-Mefloquine Combination Therapy in Trat Province, Thailand
|
N/A | |
Completed |
NCT00074841 -
Trial of Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine for the Treatment of Uncomplicated Malaria in India
|
Phase 2/Phase 3 | |
Recruiting |
NCT04416945 -
Targeting High Risk Populations With Enhanced Reactive Case Detection in Southern Lao Peoples Democratic Republic
|
N/A | |
Completed |
NCT00314899 -
Fetal Immunity to Falciparum Malaria
|
||
Completed |
NCT02867059 -
SJ733 Induced Blood Stage Malaria Challenge Study
|
Phase 1 | |
Completed |
NCT00701961 -
Pharmacokinetic of Mefloquine-Artesunate in Plasmodium Falciparum Malaria Infection in Pregnancy
|
Phase 2/Phase 3 | |
Completed |
NCT00338520 -
Hyperphenylalaninemia in Cerebral Malaria
|
N/A | |
Completed |
NCT00707200 -
The Cytoadherence in Pediatric Malaria (CPM) Study
|
N/A | |
Completed |
NCT00393757 -
Malaria Transmission and Immunity in Highland Kenya
|
||
Completed |
NCT03783299 -
Targeted Active Case Detection Among High Risk Populations in Southern Lao Peoples Democratic Republic
|
Phase 4 | |
Completed |
NCT02614404 -
Effect of Imatinib on Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum Malaria
|
Phase 1 | |
Completed |
NCT00358332 -
Phase I Pediatric FMP2.1/AS02A Trial in Mali
|
Phase 1 | |
Completed |
NCT00730782 -
Assessment of Three Formulations of the Candidate Vaccine AMA 1 in Healthy Dutch Adult Volunteers
|
Phase 1 | |
Completed |
NCT00349713 -
FMP2.1 Trial in Bandiagara, Mali
|
Phase 1 | |
Recruiting |
NCT05052502 -
Targeting High Risk Populations With Enhanced Reactive Focal Mass Drug Administration in Thailand
|
N/A | |
Completed |
NCT04093765 -
Mass Screening and Treatment for Reduction of Falciparum Malaria
|
N/A | |
Completed |
NCT03764527 -
Tolerability and Efficacy of Artemether-Lumefantrine Versus Artesunate + Amodiaquine in Zanzibar
|
Phase 4 |